0001209191-18-039973.txt : 20180628
0001209191-18-039973.hdr.sgml : 20180628
20180628193316
ACCESSION NUMBER: 0001209191-18-039973
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180626
FILED AS OF DATE: 20180628
DATE AS OF CHANGE: 20180628
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith Karen L.
CENTRAL INDEX KEY: 0001639637
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 18926788
MAIL ADDRESS:
STREET 1: C/O JAZZ PHARMACEUTICALS PLC
STREET 2: 5TH FL, WATERLOO EXCHANGE, WATERLOO RD
CITY: DUBLIN L2 4
STATE: L2
ZIP: 0
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-26
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001639637
Smith Karen L.
C/O SANGAMO THERAPEUTICS, INC.
501 CANAL BLVD.
RICHMOND
CA
94804
1
0
0
0
Common Stock
2018-06-26
4
A
0
5000
0.00
A
5000
D
Stock Option (Right to Buy)
15.65
2018-06-26
4
A
0
30000
0.00
A
2028-06-25
Common Stock
30000
30000
D
Represents shares of common stock issuable upon settlement of restricted stock units ("RSUs"). The RSUs will vest with respect to 1/3rd of the shares in three equal annual installments over the three-year period measured from the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.
Each option is immediately exercisable for all option shares, but shares purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's service on the Board of the Directors of the Issuer. The shares subject to the option vest in 36 successive equal monthly installments upon the Reporting Person's completion of each month of Board service over the 36-month period measured from the grant date.
/s/ Heather Turner, Attorney-in-Fact
2018-06-28